Breast cancer recurrence in initially clinically node-positive patients undergoing sentinel lymph node biopsy after neoadjuvant chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03

Basit Öğe Kaydı
dc.contributor.authorCabıoğlu, Neslihan
dc.contributor.authorKaranlık, Hasan
dc.contributor.authorİğci, Abdullah
dc.contributor.authorMüslümanoğlu, Mahmut
dc.contributor.authorGülçelik, Mehmet Ali
dc.contributor.authorUras, Cihan
dc.contributor.authorKoçer, Havva Belma
dc.contributor.authorTrabulus, Didem Can
dc.contributor.authorÖzkurt, Enver
dc.contributor.authorÇakmak, Güldeniz Karadeniz
dc.contributor.authorTükenmez, Mustafa
dc.contributor.authorBademler, Süleyman
dc.contributor.authorYıldırım, Nilüfer
dc.contributor.authorAkgül, Gökhan Giray
dc.contributor.authorŞen, Ebru
dc.contributor.authorŞenol, Kazım
dc.contributor.authorEmiroğlu, Selman
dc.contributor.authorÇitgez, Bülent
dc.contributor.authorErsoy, Yeliz Emine
dc.contributor.authorDağ, Ahmet
dc.contributor.authorZengel, Baha
dc.contributor.authorBaşaran, Gül
dc.contributor.authorKara, Halil
dc.contributor.authorDilege, Ece
dc.contributor.authorUğurlu, M. Ümit
dc.contributor.authorÇelik, Atilla
dc.contributor.authorİlgün, Serkan
dc.contributor.authorBölükbaşı, Yasemin
dc.contributor.authorKaraman, Niyazi
dc.contributor.authorSakman, Gürhan
dc.contributor.authorÖzbaş, Serdar
dc.contributor.authorKılıç, Halime Gül
dc.contributor.authorPolat, Ayfer Kamalı
dc.contributor.authorÖzemir, İbrahim Ali
dc.contributor.authorKılıç, Berkay
dc.contributor.authorAltınok, Ayşe
dc.contributor.authorVarol, Ecenur
dc.contributor.authorDoğan, Lütfi
dc.contributor.authorAkcan, Alper
dc.contributor.authorÖzçınar, Beyza
dc.contributor.authorZer, Leyla
dc.contributor.authorSoyder, Aykut
dc.contributor.authorVelidedeoğlu, Mehmet
dc.contributor.authorErözgen, Fazilet
dc.contributor.authorGöktepe, Berk
dc.contributor.authorDoğan, Mutlu
dc.contributor.authorKebudi, Abut
dc.contributor.authorYiğit, Banu
dc.contributor.authorÇelik, Burak
dc.contributor.authorYormaz, Serdar
dc.contributor.authorArıcı, Cumhur
dc.contributor.authorAğcaoğlu, Orhan
dc.contributor.authorSevinç, Ali İbrahim
dc.contributor.authorAtahan, M. Kemal
dc.contributor.authorValiyeva, Vafa
dc.contributor.authorBaran, Elif
dc.contributor.authorAljorani, Israa
dc.contributor.authorUtkan, Zafer
dc.contributor.authorYeniay, Levent
dc.contributor.authorKıvılcım, Taner
dc.contributor.authorSoran, Atilla
dc.contributor.authorAydıner, Adnan
dc.contributor.authorİbiş, Kamuran
dc.contributor.authorÖzmen, Vahit
dc.date.accessioned2024-12-10T11:31:14Z
dc.date.available2024-12-10T11:31:14Z
dc.date.issued2024en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractBackground: This study aims to identify factors predicting recurrence and unfavorable prognosis in cN+ patients who have undergone sentinel lymph node biopsy (SLNB) following neoadjuvant chemotherapy (NAC). Methods: The retrospective multi-centre "MF18-02" and the prospective multi-centre cohort registry trial "MF18-03" (NCT04250129) included patients with cT1-4N1-3M0 with SLNB+/- axillary lymph node dissection (ALND) post-NAC. Results: A total of 2407 cN+ patients, who later achieved cN0 status after NAC and subsequently underwent SLNB, were studied. The majority had cT1-2 (79.1%) and N1 (80.7%). After a median follow-up time of 41 months, the rates of locoregional recurrence and axillary recurrence (AR) were 1.83% and 0.37%, respectively. No significant difference in locoregional recurrence or AR rates was observed between the SLNB/targeted axillary dissection-only (n = 1470) and ALND (n = 937) groups. Factors significantly linked with AR included age younger than 45 years, nonpathological complete response (non-pCR) in the breast, and nonluminal pathology. Locoregional recurrences were associated with nonluminal or HER2(+) pathology, non-pCR in the breast, and ALND. Poor prognostic factors for disease-free survival (DFS) included having cT3-T4, no breast pCR (non-pCR), ypN(+), and nonluminal pathology. No significant difference was found in DFS or disease-specific survival (DSS) rates among ypN0, ypN-isolated tumour cells, ypNmic, and ypN1. However, significant decreases in DFS and DSS rates were observed when comparing ypN2 or ypN3 disease with ypN0. Conclusions: The present large registry data indicate that younger patients (<45), those with nonluminal pathology, and those who only partially respond in the breast are more susceptible to axillary and locoregional recurrences.en_US
dc.identifier.citationCabioglu, N., Karanlik, H., Igci, A., Muslumanoglu, M., Gulcelik, M. A., Uras, C., ... & Ozmen, V. (2024). Breast cancer recurrence in initially clinically node-positive patients undergoing sentinel lymph node biopsy after neoadjuvant chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03. Annals of Surgical Oncology, 32(2), 952-966. 10.1245/s10434-024-16472-6en_US
dc.identifier.endpage966en_US
dc.identifier.issn1068-9265
dc.identifier.issn1534-4681
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85211486057
dc.identifier.scopusqualityQ1
dc.identifier.startpage952en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12939/5081
dc.identifier.volume32en_US
dc.identifier.wosWOS:001376815300001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAltınok, Ayşe
dc.language.isoen
dc.relation.ispartofAnnals of Surgical Oncology
dc.relation.isversionof10.1245/s10434-024-16472-6en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAxillary dissectionen_US
dc.subjectAxillary recurrenceen_US
dc.subjectBreast cancer recurrenceen_US
dc.subjectLocoregional recurrenceen_US
dc.subjectNeoadjuvant chemotherapyen_US
dc.subjectNon-luminal pathologyen_US
dc.subjectRegional nodal irradiationen_US
dc.subjectSentinel lymph node biopsyen_US
dc.subjectSurvivalen_US
dc.subjectYoung ageen_US
dc.titleBreast cancer recurrence in initially clinically node-positive patients undergoing sentinel lymph node biopsy after neoadjuvant chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu